Latest filing published 21 Jan 2026 for Cabaletta Bio, Inc., €21k.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Gwendolyn Binder on record concern Cabaletta Bio, Inc. Over a trading history stretching from 18 October 2022 to 21 January 2026, the count stands at 27 filings.
In open-market terms, that means 2 purchases worth €41k on one side and 16 sales worth €1.6M on the other. Taken together, the sales exceed the purchases by €1.5M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 9 option exercises. Since January 2026: 1 purchase and no sales on the market.
On 21 January 2026 came the latest disclosure, an open-market purchase for €21k in Cabaletta Bio, Inc. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 27 declarations